(Q41393114)

30 September 2017

1 reference

title

Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies (English)

1 reference

30 September 2017

1 reference

Deo YM

1

1 reference

30 September 2017

Graziano RF

series ordinal

2

1 reference

30 September 2017

Repp R

series ordinal

3

1 reference

30 September 2017

van de Winkel JG

series ordinal

4

1 reference

30 September 2017

publication date

1 March 1997

1 reference

30 September 2017

1 reference

30 September 2017

volume

18

1 reference

30 September 2017

issue

3

1 reference

30 September 2017

page(s)

127-135

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

30 September 2017

1 reference

7 January 2021

Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Sequences of complementary DNAs that encode the NA1 and NA2 forms of Fc receptor III on human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Fc gamma receptor IIIb enhances Fc gamma receptor IIa function in an oxidant-dependent and allele-sensitive manner

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Cytotoxic antibodies trigger inflammation through Fc receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Inhibition of hepatic metastases of human colon cancer in nude mice by a chimeric SF-25 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

IgM anti-Fc gamma R autoantibodies trigger neutrophil degranulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2897%2901007-4

7 January 2021

10.1016/S0167-5699(97)01007-4

Identifiers

DOI

1 reference

30 September 2017

1 reference